Radiomics for predicting perineural invasion status in rectal cancer

doi:10.3748/wjg.v27.i33.5610

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5315)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

363

WORD

127

HTML

3089

Figures (1-5)

242

Tables (1-4)

172

Sum=3993

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

409

Download

913

Sum=1322

Sep 7, 2021 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 7, 2021; 27(33): 5610-5621
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5610

Table 1 Baseline characteristics of the study population

Characteristics	PNI⁺ (n = 144)	PNI^-(n = 159)	P value	The training set(n = 242)	The validation set(n = 61)	P value
Age (mean ± SD, yr)	58.9 ± 11.8	58.9 ± 11.7	0.952	58.4 ± 11.9	60.8 ± 10.2	0.162
Sex (male/female)	77/67	93/66	0.379	140/102	30/31	0.223
Volume (cm³)	19.7	20.8	0.132	20.1	20.8	0.847
Location¹			0.075			0.045
Middle-low	101	96		164	33
High	43	63		78	28
cT stage (T1-2/T3/T4)	25/98/21	57/90/12	< 0.001	61/156/25	21/32/8	0.222
cN stage (N0/N1/N2)	31/52/61	75/59/25	< 0.001	89/84/69	17/27/17	0.313
Neoadjuvant therapy (+/-)	25/119	37/122	0.203	51/191	11/50	0.599
CEA (+/-) (positive ≥ 5 ng/mL)	77/67	56/103	0.001	107/135	26/35	0.823
CA19-9 (+/-) (positive ≥ 30 U/mL)	43/101	35/124	0.119	64/178	14/47	0.577
CA125 (+/-) (positive ≥ 24 U/mL)	20/124	15/144	0.226	20/222	3/58	0.378
pT stage (T1/T2/T3/T4)	0/15/117/12	8/44/95/12	< 0.001	6/48/171/17	2/11/41/7	0.584
pN stage (0/N1/N2)	29/74/41	81/56/22	< 0.001	88/101/53	22/29/10	0.579
Stage (Ⅰ/Ⅱ/Ⅲ)	10/28/115	38/43/78	< 0.001	40/48/154	8/14/39	0.731
Histologic grade (G1/G2/G3)	1/105/38	2/133/24	0.014	2/189/51	1/49/11	0.523
Rad-score	0.60 ± 0.19	0.40 ± 0.20	< 0.001	0.50±0.21	0.49 ± 0.23	0.805

¹Location: Low (0-5 cm from the anal verge), middle (5.1-10 cm from the anal verge), and high (10.1-15 cm from the anal verge). This table summarized the results of cT-stage and cN-stage for the two readers. CT: Computed tomography; PNI: Perineural invasion; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; cT stage: Computed tomography-reported T stage; cN stage: Computed tomography-reported N stage; pT stage: Pathological T stage; pN stage: Pathological N stage.

Table 2 Risk factors selected by logistic regression analysis

Variables	Univariate		Multivariate
	OR	P value	OR	P value
Age	1.001	0.961	-	-
Sex	0.787	0.358	-	-
Volume	1.000	1.000	-	-
Location	1.779	0.050	1.470	0.265
cT stage	2.328	< 0.001	1.636	0.087
cN stage	1.550	< 0.001	1.458	0.001
CEA	2.631	< 0.001	2.528	0.003
CA19-9	1.478	0.182	-	-
CA125	0.717	0.484	-	-
Rad-score	3.012	< 0.001	3.148	< 0.001

If P value < 0.1, variables were included in the model. CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; OR: Odds ratio.

Table 3 Comparisons of variables and models in the training and validation cohorts

	The training set				The validation set
	AUC	SEN (%)	SPE (%)	P value	AUC	SEN (%)	SPE (%)	P value
CEA	0.597 (0.533-0.660)	50.00	76.38	< 0.001	0.635 (0.502-0.754)	96.55	40.63	0.042
cT stage	0.613 (0.549-0.675)	84.35	33.86	< 0.001	0.589 (0.456-0.714)	75.86	43.75	0.004
cN stage	0.670 (0.607-0.729)	42.61	84.25	< 0.001	0.684 (0.553-0.797)	86.21	40.63	0.045
Rad-score	0.760 (0.701-0.812)	72.17	69.29	0.020	0.782 (0.658-0.878)	68.97	78.12	0.640
Clinical model	0.718 (0.657-0.774)	63.48	70.08	< 0.001	0.674 (0.542-0.789)	65.52	71.87	0.045
Combined model	0.828 (0.774-0.873)	66.09	88.19		0.801 (0.679-0.892)	62.07	93.75

P value: Compared with the combined model by DeLong’s test. AUC: Area under the receiver operating characteristic curve; SEN: Sensitivity; SPE: Specificity; CEA: Carcinoembryonic antigen.

Table 4 Subgroup analyses of the models in the whole cohort

	The clinical model			The combined model			P value
Subgroups	AUC	SEN (%)	SPE (%)	AUC	SEN (%)	SPE (%)
nCRT
With (n = 62)	0.710 (0.581-0.818)	68.00	75.68	0.853 (0.740-0.930)	68.00	89.19	0.011
Without (n = 241)	0.712 (0.650-0.768)	48.74	83.61	0.814 (0.759-0.861)	65.55	87.70	< 0.001
Stage
II (n = 62)	0.553 (0.422-0.680)	21.05	93.02	0.670 (0.538-0.784)	36.84	100.00	0.098
III (n = 193)	0.630 (0.558-0.698)	56.52	69.23	0.796 (0.732-0.851)	73.04	79.49	< 0.001

P value: Comparisons between the clinical model and combined model. AUC: Area under the receiver operating characteristic curve; SEN: Sensitivity; SPE: Specificity; nCRT: Neoadjuvant chemoradiotherapy.

Citation: Li M, Jin YM, Zhang YC, Zhao YL, Huang CC, Liu SM, Song B. Radiomics for predicting perineural invasion status in rectal cancer. World J Gastroenterol 2021; 27(33): 5610-5621
URL: https://www.wjgnet.com/1007-9327/full/v27/i33/5610.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i33.5610